RxDoctor Payments Data

Osei Whyte, MD

Internal Medicine · Atlanta, GANPI 1669727624

Payments from drug & device makers

$2,737in general payments, 2019–2025

Across 151 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$676
  • Lilly USA, LLC$450
  • Amgen$240
  • Astellas Pharma US Inc$211
  • AbbVie$182
  • Pfizer$141
  • plus $838 from 20 others

What the payments were for

  • Food & beverage$2,737100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,737 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$83,145
Medicare patients
223
Services billed
795

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin206$199,936
OzempicSemaglutide63$88,615
TrulicityDulaglutide76$82,671
EliquisApixaban82$77,552
MounjaroTirzepatide48$56,549
ProliaDenosumab15$25,749
RybelsusSemaglutide13$21,002
JanuviaSitagliptin Phosphate19$19,203
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$18,064
MyrbetriqMirabegron14$15,135
FarxigaDapagliflozin Propanediol16$13,347
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog36$11,243
XiidraLifitegrast11$8,101
LinzessLinaclotide11$8,068
Nifedipine ErNifedipine239$5,677

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$48$199,936206 claims
Lilly USA, LLCTrulicity, Mounjaro$450$139,221124 claims
Novo NordiskOzempic, Rybelsus$676$109,61676 claims
PfizerEliquis$141$77,55282 claims
AmgenProlia$240$25,74915 claims
MerckJanuvia$76$19,20319 claims
GSKTrelegy Ellipta$37$18,06416 claims
AstraZenecaFarxiga, Symbicort$90$16,27529 claims
Astellas Pharma US IncMyrbetriq$211$15,13514 claims
AbbVieLinzess$182$8,06811 claims
Sanofi-aventis U.S. LLCLantus$36$2,51124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →